TejashriPurohit-ShethMD

PubMed

• FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma.
  Peredo-Pinto, H., Wang, C., Xu, Z., Tegenge, M., Elmacken, M., Jaigirdar, A., Theoret, M., Purohit-Sheth, T., Kasamon, Y.> ;Clinical Cancer Research. 2024 Feb 7
• 3 citations
  FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma.
  Poornima Sharma, Yvette L Kasamon, Xue Lin, Zhenzhen Xu, Marc R Theoret, Tejashri Purohit-Sheth> ;Clinical Cancer Research. 2023 Nov 1
• 10 citations
  FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
  Najat Bouchkouj, Xue Lin, Xiaofei Wang, Donna Przepiorka, Zhenzhen Xu, Tejashri Purohit-Sheth, Marc Theoret> ;The Oncologist. 2022 Oct 1
• 3 citations
  FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma.
  Najat Bouchkouj, Megan Zimmerman, Yvette L Kasamon, Cong Wang, Tianjiao Dai, Zhenzhen Xu, Xiaofei Wang, Marc Theoret, Tejashri Purohit-Sheth, Bindu George> ;The Oncologist. 2022 Jul 5
• 21 citations
  Clinical Development of Gene Therapies: The First Three Decades and Counting.
  Larissa Lapteva, Tejashri Purohit-Sheth, Mercedes A. Serabian, Raj K. Puri> ;Molecular Therapy. Methods & Clinical Development. 2020 Oct 10
• 8 citations
  Regenerative Medicine Therapies for Rare Diseases
  Larissa Lapteva, Ramjay Vatsan, Tejashri Purohit-Sheth> ;Translational Science of Rare Diseases. 2018 Dec 20
• 7 citations
  Oral allergy syndrome (pollen-food allergy syndrome).
  Tejashri S Purohit-Sheth, Warner W Carr> ;Allergy and Asthma Proceedings. 2005 May 1
• Join now to see all